Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Section Content Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail
-

Risperdal Consta (risperidone) long-acting injection

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – August 2010

Summary View

ADVERSE REACTIONS

Other Adverse Reactions Observed During the Premarketing Evaluation of Risperdal Consta
  • abdominal pain upper, respiratory tract infection, glucose urine present, initial insomnia, ejaculation delayed, pruitus generalized
Postmarketing Experience
  • urinary retention, diabetes mellitus and hypoglycemia
-
-